132 related articles for article (PubMed ID: 19635185)
21. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.
Björkholm M; Ohm L; Eloranta S; Derolf A; Hultcrantz M; Sjöberg J; Andersson T; Höglund M; Richter J; Landgren O; Kristinsson SY; Dickman PW
J Clin Oncol; 2011 Jun; 29(18):2514-20. PubMed ID: 21576640
[TBL] [Abstract][Full Text] [Related]
22. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
23. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
24. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
Albajar M; Gutierrez P; Richard C; Rosa-Garrido M; Gómez-Casares MT; Steegmann JL; León J; Delgado MD
Cancer Lett; 2008 Nov; 270(2):328-36. PubMed ID: 18635311
[TBL] [Abstract][Full Text] [Related]
25. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
26. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
27. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
28. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
29. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
Xu N; Ouyang Z; DU QF; Wang S; Yang J; Wang Y; Liu XL
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):25-8. PubMed ID: 21429397
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
32. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
33. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.
Muramatsu H; Takahashi Y; Sakaguchi H; Shimada A; Nishio N; Hama A; Doisaki S; Yagasaki H; Matsumoto K; Kato K; Kojima S
Int J Hematol; 2011 Feb; 93(2):186-191. PubMed ID: 21234820
[TBL] [Abstract][Full Text] [Related]
34. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
35. Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.
Vandyke K; Fitter S; Drew J; Fukumoto S; Schultz CG; Sims NA; Yeung DT; Hughes TP; Zannettino AC
J Clin Endocrinol Metab; 2013 Jan; 98(1):67-76. PubMed ID: 23144472
[TBL] [Abstract][Full Text] [Related]
36. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
37. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
38. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
40. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
